Circular-Lab

Method

Take control of the pandemic. No improvisation

Thanks to our software and its methodology, Connect by Circular-Lab© provides a modular and adaptable technological solution to your company’s casuistry that allows:
  1. Quickly identify risk situations, with automatic alerts and action protocols to prevent the spread of the virus in the organization.

  2. Manage the chaos that can be caused by the coincidence among COVID-19 outbreaks. Circular-Lab and its technology can help you discern COVID-19 from flus or colds, both with similar symptomatology, quickly discerning between them to protect and resume your activity without any delay.

  3. Be ahead of possible COVID-19 outbreaks and quarantines to avoid eventual shutdowns of your activity.

Circular-Lab tools allow automation and maximization of the efficiency of population testing for Covid-19, optimizing the diagnostic value chain by digitizing processes and traceability to reduce human error (>30%):

  • Automation and digitization of testing processes, integration and analysis of population data and management of population testing for epidemiology / seroprevalence studies.
  • Validation of vaccines, tests and treatments, and planning and management of vaccination campaigns.
  • Tracking applications and alarm systems linked to laboratories, health centers and hospital network.
  • Health security management of infrastructures and essential sectors, ministries and government agencies.


Efficient screening and monitoring algorithms with Artificial Intelligence and Machine Learning tools. Quickly identify risk situations, with automatic alerts and action protocols to prevent the spread of the virus in the organization.

Our method

FIRST STEP. Smart testing

SECOND STEP. Automated test management

  1. Realización de un cuestionario a toda la plantilla basado en parámetros epidemiológicos, demográficos y personales.
  2. Estas respuestas se trasladan a nuestros algoritmos inteligentes realizando una segmentación de la plantilla de tu organización en función de criterios de vulnerabilidad y de riesgo:- Empleados de riesgo alto
    – Empleados de riesgo moderado
    – Empleados de riesgo bajo
  3. Una vez identificados los trabajadores por riesgo de infección, nuestros algoritmos arrojan un patrón de cribado recomendando qué tests debe realizarse a cada grupo de riesgo para mantener en todo momento la seguridad de tu plantilla.
  4. Monitorización periódica de la situación de tus empleados para velar por su seguridad de forma coste-eficiente. Nuestros algoritmos se adaptan a la casuística de tu organización.

Stop worrying about test logistics management.

You can see in real time the results on your tracking dashboard. Circular-Lab has digitized and automated all steps of the testing chain for efficient and safe operation, reducing the need for management and human error.

    1. Dumping of your organization’s data on our platform.

    2. Automated management of the extraction and test performance according to the screening pattern by algorithm in the clinic / SPRL / Laboratory agreed upon.

    3. Laboratory analysis and digital report with specific recommendations for action.
    4. Sending information to the Dashboard (control panel) of the company’s manager for alerts and planning.

THIRD STEP. Longitudinal monitoring

Data traceability and continuous monitoring: Circular-Lab’s tools allow you to have a system of automation and digitization of your workforce data to obtain real-time information and take control of the situation. Our tools are:

  1. Generation of a dynamic QR: a dynamic, personal and non-transferable QR is generated for each employee identifying his or her risk group and COVID-19 status.
  2. QR reader application for access control.
  3. Automatic risk alert to prevent the spread of the virus and that your activity is affected as little as possible.
  4. Alert by proximity and geographical distribution: employee traceability for rapid identification of individuals who have had close contact with an infected or at-risk employee, or rapid identification of regional or company headquarters outbreaks.
  5. Design of action protocols adapted to the casuistry of your organization.
  6. Self-reporting application: any person who has been exposed or has symptoms, has at his/her disposal an interactive tool for symptom management, and an alert notification button that would appear on the manager’s dashboard and would be automatically communicated to employees who have had contact (optional). The action protocol is initiated to stop the spread of the virus in your organization.
  7. Reporting – KPIs: Report and interpretation of the results visually on the manager’s dashboard, customizable for the KPIs of interest.

INNOVATION

Technological singularities

Asset 9
flecha
  1. Circular-Lab © is designed to store and process large amounts of data.
  2. Analysis with Big Data toolsMachine Learning algorithmsand Artificial Intelligence.
  3. Study of trends and evolution, epidemiology, seroprevalence, preventive medicine or anticipation of situations, among other elements.
Asset 10
flecha
  1. Centralization of data in real time.
  2. More advanced digital tools and cybersecurity.
  3. Truthful and robust analysis of situations and trends related to Covid-19.
  4. Data traceability.
  5. Inform management decisions, optimize processes and action protocols.
Asset 11
flecha
  1.  
  2. Distributed and immutable databases.
  3. Unlimited data collection capacity, given its architecture and design.
Asset 12
flecha
  1. Tools for ingesting and importing data from different sources (public and private databases, hospitals, laboratories, health centers, control readers).
  2. Data structuring for subsequent analysis.
  3. Versatility of adaptation to other tools while maintaining security and encryption criteria.

What makes us different?

WITH CIRCULAR LAB

BEFORE CIRCULAR LAB

Anticipation and efficency

.

Out of control and update

Automation and efficiency.

Take control of the situation.

Cost-efficient testing based on need.

Clear and efficient acing protocols.

Continuous monitoring and traceability.

Risks prevention.

Lack of knowledge of casuistry.

Lack of knowledge of carried out tests.

Lack of knowledge of real risk.

Unclear and inefficient acting protocols.

Inability to monitor.

Difficulty in planning.

Would you like to know more?